Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (2968)	9/23/1998 11:15:00 AM
From: Michael Bidder	Respond to of 4634

Very hard to time. Its a real pain trying to pick one like this. How on earth Bill do they beat it up against all the selling? Is it Sacrificial fund money? Michael Bidder

To: Bill Wexler who wrote (2968)	9/23/1998 5:03:00 PM
From: Michael Bidder	Respond to of 4634

Yes it is all over the map. A traders dream. This from (yahoo#499) If HE2000 as a monotherapy shows efficacy and little toxicity, I have to think that the company would release that data as soon as possible. Is HE2000 the next asprine, or AZT? Whats a monotherapy? What's the basis for of Fraud? Michael Bidder....full of questions

To: Bill Wexler who wrote (2968)	9/23/1998 6:26:00 PM
From: Bill Wexler	Read Replies (1) \| Respond to of 4634

The TAVA fraud disappoints investors....again. I continue to be 100% correct about the TAVA fraud. After months of fraudulent promotion, hype and nonsense being spread about this financially weak It consulting firm, the new "earnings" report has demonstrated once again that TAVA management can not deliver the goods, and investors that pin their hopes on a one time event (Y2K) are going to be seriously disappointed. I reiterate my strong sell recommendation for TAVA.